Betty J Nelson

Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis

Brett P. Giroir, Peter A. Quint, Phil Barton et al. · The Lancet · 1997 · 182 citations

Recombinant Amino-terminal Fragment, Medical Microbiology, Pathology +10

Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF^V600E</i>-mutated melanoma.

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · Journal of Clinical Oncology · 2012 · 139 citations

Clinical Endpoint, Prognosis, Immunology +22

Inhibition of Endotoxin-Induced Cytokine Release and Neutrophil Activation in Humans by Use of Recombinant Bactericidal/Permeability-Increasing Protein

M. A. M. Von Der Möhlen, A N Kimmings, Nancy Wedel et al. · The Journal of Infectious Diseases · 1995 · 123 citations

Neutrophil Activation, Endotoxin Levels, Immunology +18

Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies

Vibeke Strand, Peter E. Lipsky, Grant W. Cannon et al. · Arthritis & Rheumatism · 1993 · 79 citations

Bactericidal/Permeability-Increasing Protein (rBPI21) in Patients with Hemorrhage Due to Trauma

J. Stanley Smith, Lewis E. Jacobson, Michael Moncure et al. · 1999 · 57 citations